Study of new drug combo for extensive-stage small-cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have extensive-stage small-cell lung cancer (cancer that has spread to both lungs or beyond).
- You cannot have had any prior treatment for this cancer.
- You must be able to do your daily activities with little to no help (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a scan.
- You must have adequate organ function (kidneys, liver, heart, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a new combination of drugs (QL1706, anti-angiogenesis therapy, and chemotherapy) for people with extensive-stage small cell lung cancer who have not received any prior treatment. The goal is to see if this combination works better than standard care.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This early-phase trial tests a new combination of drugs (HS-20093 plus other treatments) for people with extensive-stage small cell lung cancer whose cancer has not grown after their first round of treatment. The goal is to see if this new approach can keep the cancer from coming back.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.